Acquisition of Voluntis’ shares by AptarGroup,Inc
Debiopharm Statement regarding its Strategic Committee Members
Debiopharm interviewed by Biotech Finances to talk about our evergreen fund
Voluntis on receiving FDA 510(K) Clearance and expanding
Voluntis on receiving the CE Mark for Oleena
Voluntis expanding their global pharma collaborations
Novadiscovery announces new clinical simulation collaboration with Takeda
Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant
Nucleai Partners With Sheba Medical Center’s ARC Innovation Center For a New Strategic Data Collaboration
